drugset / Trial / NCT06720233

Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis

NCT06720233

Phase 3 Completed 37 enrolled Shenzhen Salubris Pharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in Chinese patients receiving peritoneal dialysis with chronic kidney disease and anemia

Timeline

Start
2002-02-22
Primary completion
2024-10-18
Completion
2024-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject SAL-0951 Unknown 1 mg
Subject SAL-0951 Unknown 8 mg

Indications